Overview
- Veeva reported fiscal Q2 results on Aug. 26 with revenue of $928 million and raised full‑year FY2027 guidance to about $3.68–3.69 billion.
- Subscription revenue grew about 16% to $766.8 million and company‑defined non‑GAAP operating income was roughly $416 million, leaving non‑GAAP margins near the mid‑40s.
- Vault CRM delivered a record quarter with new selections by Eli Lilly, Biogen and Regeneron and commitments from 12 of the top 20 biopharma companies, supporting cross‑product sales.
- The stock jumped roughly 20% the next trading day and nearly 20 analysts raised price targets, while management pointed to the Nov. 5 investor day as the next major event for the AI roadmap.
- Reported GAAP operating income rose sharply but comparisons were aided by a prior‑year $30.6 million litigation charge, and management says Veeva Falcon AI is accelerating yet remains an early, unquantified revenue opportunity.